Claims
- 1. A method of identifying a compound that induces apoptosis in a cell, comprising:
a. contacting the cell with a putative apoptosis-inducing compound; b. determining whether the compound inhibits a target selected from the group consisting of APLP2, ENSA, FBN2, FIBL-6, PRNP, STRN4, XPR1, SLC5A6, SLC31A1, GFER, and PCTK1.
- 2. The method, as claimed in claim 1, wherein the target has been validated as being involved in tumor cell growth.
- 3. The method, as claimed in claim 2, wherein the target has been validated as being involved in tumor cell growth by a process comprising;
a. inhibiting the target in a cell by a method selected from the group consisting of gene knock-out, anti-sense oligonucleotide expression, use of RNAi molecules and GSE expression; b. assaying the cell for the ability of the cell to grow.
- 4. The method, as claimed in claim 1, wherein the cell is selected from tumor cell lines.
- 5. The method, as claimed in claim 1, wherein the step of determining is selected from the group consisting:
a. assaying for reduced expression of the target; and b. assaying for reduced activity of the target.
- 6. The method, as claimed in claim 5, wherein the expression of the target is measured by polymerase chain reaction.
- 7. The method, as claimed in claim 5, wherein the expression of the target is measured using an antibody that specifically recognizes the target.
- 8. The method, as claimed in claim 5, wherein the activity of the target is measured by measuring the amount of a product generated in a biochemical reaction mediated by the target.
- 9. The method, as claimed in claim 5, wherein the activity of the target is measured by measuring the amount of a substrate consumed in a biochemical reaction mediated by the target.
- 10. The method, as claimed in claim 1, wherein the inhibitor is identified by:
a. determining the three-dimensional structure of the target; and b. determining the three-dimensional structure of an inhibitor by using computer software capable of modeling the interaction of the target and putative test compounds.
- 11. The method, as claimed in claim 1, wherein the compound that induces apoptosis inhibits growth of tumor cells.
- 12. The method, as claimed in claim 1, wherein the target is APLP2.
- 13. The method, as claimed in claim 1, wherein the target is ENSA.
- 14. The method, as claimed in claim 1, wherein the target is FBN2.
- 15. The method, as claimed in claim 1, wherein the target is FIBL-6.
- 16. The method, as claimed in claim 1, wherein the target is PRNP.
- 17. The method, as claimed in claim 1, wherein the target is STRN4.
- 18. The method, as claimed in claim 1, wherein the target is XPR1.
- 19. The method, as claimed in claim 1, wherein the target is SLC5A6.
- 20. The method, as claimed in claim 1, wherein the target is SLC31A1.
- 21. The method, as claimed in claim 1, wherein the target is GFER.
- 22. The method, as claimed in claim 1, wherein the target is PCTK1.
- 23. A method for inducing apoptosis in a cell by inhibiting a target selected from the group consisting of APLP2, ENSA, FBN2, FIBL-6, PRNP, STRN4, XPR1, SLC5A6, SLC31A1, GFER, and PCTK1.
- 24. The method, as claimed in claim 23, wherein the target has been validated as being involved in tumor cell growth.
- 25. The method, as claimed in claim 24, wherein the target has been validated as being involved in tumor cell growth by a process comprising;
a. inhibiting the target in a cell by a method selected from the group consisting of gene knock-out, anti-sense oligonucleotide expression, use of RNAi molecules and GSE expression; b. assaying the cell for the ability of the cell to grow.
- 26. The method, as claimed in claim 23, wherein the step of inhibiting is conducted by contacting a cell with an inhibitor of the target and the inhibitor induces apoptosis in the cell.
- 27. The method, as claimed in claim 23, wherein the target is APLP2.
- 28. The method, as claimed in claim 23, wherein the target is ENSA.
- 29. The method, as claimed in claim 23, wherein the target is FBN2.
- 30. The method, as claimed in claim 23, wherein the target is FIBL-6.
- 31. The method, as claimed in claim 23, wherein the target is PRNP.
- 32. The method, as claimed in claim 23, wherein the target is STRN4.
- 33. The method, as claimed in claim 23, wherein the target is XPR1.
- 34. The method, as claimed in claim 23, wherein the target is SLC5A6.
- 35. The method, as claimed in claim 23, wherein the target is SLC31A1.
- 36. The method, as claimed in claim 23, wherein the target is GFER.
- 37. The method, as claimed in claim 23, wherein the target is PCTK1.
- 38. A method for the diagnosis of a tumor comprising determining the level of a marker in a patient sample, the level of the marker being indicative of the presence of tumor cells, wherein the marker is selected from the group consisting of APLP2, ENSA, FBN2, FIBL-6, PRNP, STRN4, XPR1, SLC5A6, SLC31A1, GFER, and PCTK1.
- 39. The method as claimed in claim 38, wherein the level of the marker is determined by identifying the marker as a cell surface molecule in tissue.
- 40. The method as claimed in claim 38, wherein the level of the marker is determined by detecting the marker in soluble form in a bodily fluid.
- 41. The method as claimed in claim 40, wherein the bodily fluid is serum.
- 42. The method as claimed in claim 40, wherein the marker level is determined by contacting a patient sample with an antibody, or a fragment thereof, that binds specifically to the marker and determining whether the anti-marker antibody or fragment thereof has bound to the marker.
- 43. The method as claimed in claim 40, wherein the marker level is determined using a first monoclonal antibody that binds specifically to the marker and a second antibody that binds to the first antibody.
- 44. The method as claimed in claim 40, wherein the bodily fluid is immobilized.
- 45. The method as claimed in claim 38, wherein the method is used to determine the prognosis for cancer in the patient.
- 46. The method as claimed in claim 38, wherein the method is used to determine the susceptibility of the patient to a therapeutic treatment.
- 47. The method, as claimed in claim 38, wherein the target is APLP2.
- 48. The method, as claimed in claim 38, wherein the target is ENSA.
- 49. The method, as claimed in claim 38, wherein the target is FBN2.
- 50. The method, as claimed in claim 38, wherein the target is FIBL-6.
- 51. The method, as claimed in claim 38, wherein the target is PRNP.
- 52. The method, as claimed in claim 38, wherein the target is STRN4.
- 53. The method, as claimed in claim 38, wherein the target is XPR1.
- 54. The method, as claimed in claim 38, wherein the target is SLC5A6.
- 55. The method, as claimed in claim 38, wherein the target is SLC31A1.
- 56. The method, as claimed in claim 38, wherein the target is GFER.
- 57. The method, as claimed in claim 38, wherein the target is PCTK1.
REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Patent Application No. 60/381,619, filed on May 17, 2002, which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60381619 |
May 2002 |
US |